Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NESCIO neoadjuvant immunotherapy trial in high-risk non-metastatic clear cell renal cell carcinoma
NL-OMON52016Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab, relatlimab in clear cell renal cell carcinoma (ccRCC), sponsored by Netherlands Cancer Institute. Started Apr 2022; status: recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON52016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52016.